<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661267</url>
  </required_header>
  <id_info>
    <org_study_id>RGX2020-RCT02</org_study_id>
    <nct_id>NCT04661267</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Regenexx Stem Cell Support Formula</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of Regenexx Stem Cell Support Formula</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenexx, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenexx, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regenexx, LLC developed a nutritional supplement formula containing many components related&#xD;
      to supporting healthy joints This oral, liquid supplement is intended to help improve joint&#xD;
      and cartilage health while also increasing their joint function. The goal of this study is to&#xD;
      measure changes in joint health and function for patients with knee OA taking this supplement&#xD;
      for 2 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a double-blind, randomized, placebo-controlled multicenter study. Liquid&#xD;
      Regenexx Stem Cell Support Formula compared to placebo control administered via oral&#xD;
      application for 2 months to determine effect on knee function and pain in patients with knee&#xD;
      OA.&#xD;
&#xD;
      Treatment group: Forty patients randomized to the treatment group will receive daily doses of&#xD;
      stem cell support formula for 60 days. Patients will complete patient-reported outcome&#xD;
      questionnaires at 1 month and 2 months.&#xD;
&#xD;
      Control group: Forty patients randomized to the control group will receive a daily doses of&#xD;
      placebo stem cell support formula for 60 days. Patients will complete patient-reported&#xD;
      outcome questionnaires at 1 month and 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower Extremity Function Scale (LEFS) change from baseline</measure>
    <time_frame>Change from baseline to 2 months</time_frame>
    <description>The difference between groups of the within patient mean change from baseline to 2 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Clinically Important Difference (MCID) for LEFS</measure>
    <time_frame>2 months</time_frame>
    <description>Percentage of patients meeting the MCID for LEFS at 2 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Function Scale (LEFS) change from baseline</measure>
    <time_frame>Change from baseline to 1 month</time_frame>
    <description>The difference between groups of the within patient mean change from baseline to 1 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee (IKDC) Subjective Knee Evaluation change from baseline</measure>
    <time_frame>Change from baseline to 2 months</time_frame>
    <description>The difference between groups of the within patient mean change from baseline to 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee (IKDC) Subjective Knee Evaluation change from baseline</measure>
    <time_frame>Change from baseline to 1 months</time_frame>
    <description>The difference between groups of the within patient mean change from baseline to 1 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Clinically Important Difference (MCID) for IKDC</measure>
    <time_frame>2 months</time_frame>
    <description>Percentage of patients meeting the MCID for IKDC at 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Pain Score (NPS) change from baseline</measure>
    <time_frame>Change from baseline to 1 months</time_frame>
    <description>The difference between groups of the within patient mean change from baseline to 1 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric Pain Score (NPS) change from baseline</measure>
    <time_frame>Change from baseline to 2 months</time_frame>
    <description>The difference between groups of the within patient mean change from baseline to 2 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Clinically Important Difference (MCID) for NPS</measure>
    <time_frame>2 months</time_frame>
    <description>Percentage of patients meeting the MCID for NPS at 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Assessment Numeric Evaluation (SANE)-modified</measure>
    <time_frame>1 month</time_frame>
    <description>The difference between groups for mean improvement scores at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Assessment Numeric Evaluation (SANE)-modified</measure>
    <time_frame>2 months</time_frame>
    <description>The difference between groups for mean improvement scores at 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Thru 2 months</time_frame>
    <description>Any complication or adverse event reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional medications or treatments</measure>
    <time_frame>Thru 2 months</time_frame>
    <description>Any additional treatments or medications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Supplement formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the experimental group will receive daily 1-ounce doses of stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to the control group will receive a daily 1-ounce doses of placebo stem cell support formula for 60 days. Patients will complete patient-reported outcome questionnaires at 1 month and 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Stem Cell Support Formula</intervention_name>
    <description>This liquid supplement contains the following ingredients: chondroitin sulfate, glucosamine sulfate, vitamin C (ascorbic acid), curcumin and Bioperine®, resveratrol, L-carnosine, bitter melon, and vitamin D.</description>
    <arm_group_label>Supplement formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo comparator will look and taste similar without the active ingredients of the Stem Cell Support Formula.</description>
    <arm_group_label>Placebo formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary signature of the IRB approved Informed Consent&#xD;
&#xD;
          2. Unilateral or bilateral osteoarthritic male or female ages 18-80&#xD;
&#xD;
          3. Pain, swelling, and/or functional disability in the affected knee consistent with&#xD;
             osteoarthritis in the knee joint&#xD;
&#xD;
          4. Physical examination consistent with osteoarthritis in knee joint&#xD;
&#xD;
          5. Kellgren-Lawrence grade 2 or 3 knee osteoarthritis and/or diagnostic MRI imaging of&#xD;
             the affected knee showing osteoarthritis (i.e. chondral loss, fissuring, defect, bone&#xD;
             marrow lesion, meniscus tear, synovial thickening, etc.)&#xD;
&#xD;
          6. Minimum of 3/10 on NPS approximately 3 days per week&#xD;
&#xD;
          7. Is independent, ambulatory, and can comply with all post-operative evaluations and&#xD;
             visits&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          8. Previously taken the Regenexx Stem Cell Support Formula&#xD;
&#xD;
          9. Receiving active knee treatment or any knee injections of any type within 3 months&#xD;
             prior to the study (steroids, biologics, etc)&#xD;
&#xD;
         10. Knee surgery within 6 months prior to the study&#xD;
&#xD;
         11. Currently taking or history of taking products that contain curcuminoid extract within&#xD;
             the last 2 weeks&#xD;
&#xD;
         12. Dependent on NSAIDs or acetaminophen for exercise or daily activities&#xD;
&#xD;
         13. Currently taking or previously taken fish oil in the last 2 weeks&#xD;
&#xD;
         14. Currently taking or previously taking MSM or glucosamine in the last 2 weeks&#xD;
&#xD;
         15. Diabetic&#xD;
&#xD;
         16. Inflammatory or auto-immune based joint diseases or other lower extremity pathology&#xD;
             (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis,&#xD;
             polymyalgia, polymyositis, gout pseudogout)&#xD;
&#xD;
         17. Quinolone or statin-induced myopathy/tendinopathy&#xD;
&#xD;
         18. Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh&#xD;
&#xD;
         19. Contraindications for MRI&#xD;
&#xD;
         20. Condition represents a worker's compensation case&#xD;
&#xD;
         21. Currently involved in a health-related litigation procedure&#xD;
&#xD;
         22. Is pregnant or breastfeeding&#xD;
&#xD;
         23. Currently taking immunosuppressive medication&#xD;
&#xD;
         24. Allergy or intolerance to study medication&#xD;
&#xD;
         25. Use of chronic opioid&#xD;
&#xD;
         26. Documented history of drug abuse within six months of treatment&#xD;
&#xD;
         27. Blood clotting disorder, taking an anticoagulant or history of cardiovascular disease&#xD;
&#xD;
         28. Has asthma&#xD;
&#xD;
         29. History of prostate cancer&#xD;
&#xD;
        29) Any other condition, that in the opinion of the investigator, that would preclude the&#xD;
        patient from enrollment including current supplement use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Centeno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regenexx, LLC and Centeno-Schultz Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ehren Dodson, PhD</last_name>
    <phone>7202877199</phone>
    <email>edodson@regenexx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neven Steinmetz, PhD</last_name>
    <phone>303-429-6448</phone>
    <phone_ext>141</phone_ext>
    <email>nsteinmetz@regenexx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centeno-Schultz Clinic</name>
      <address>
        <city>Broomfield</city>
        <state>Colorado</state>
        <zip>80021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Speer, MBA</last_name>
      <email>espeer@centenoschultz.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Centeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Schultz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Pitts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Markle, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Hyzy, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centeno-Schultz Clinic</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Speer</last_name>
      <phone>303-429-6448</phone>
      <email>espeer@centenoschultz.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Centeno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Hyzy, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Someya A, Ikegami T, Sakamoto K, Nagaoka I. Glucosamine Downregulates the IL-1β-Induced Expression of Proinflammatory Cytokine Genes in Human Synovial MH7A Cells by O-GlcNAc Modification-Dependent and -Independent Mechanisms. PLoS One. 2016 Oct 24;11(10):e0165158. doi: 10.1371/journal.pone.0165158. eCollection 2016.</citation>
    <PMID>27776166</PMID>
  </reference>
  <reference>
    <citation>Jerosch J. Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheumatol. 2011;2011:969012. doi: 10.1155/2011/969012. Epub 2011 Aug 2.</citation>
    <PMID>21826146</PMID>
  </reference>
  <reference>
    <citation>Du CB, Liu JW, Su W, Ren YH, Wei DZ. The protective effect of ascorbic acid derivative on PC12 cells: involvement of its ROS scavenging ability. Life Sci. 2003 Dec 26;74(6):771-80.</citation>
    <PMID>14654169</PMID>
  </reference>
  <reference>
    <citation>D'Aniello C, Cermola F, Patriarca EJ, Minchiotti G. Vitamin C in Stem Cell Biology: Impact on Extracellular Matrix Homeostasis and Epigenetics. Stem Cells Int. 2017;2017:8936156. doi: 10.1155/2017/8936156. Epub 2017 Apr 20. Review.</citation>
    <PMID>28512473</PMID>
  </reference>
  <reference>
    <citation>Larasati YA, Yoneda-Kato N, Nakamae I, Yokoyama T, Meiyanto E, Kato JY. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. Sci Rep. 2018 Feb 1;8(1):2039. doi: 10.1038/s41598-018-20179-6.</citation>
    <PMID>29391517</PMID>
  </reference>
  <reference>
    <citation>Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, Shi X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun. 2003 Oct 3;309(4):1017-26.</citation>
    <PMID>13679076</PMID>
  </reference>
  <reference>
    <citation>Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014 Jan;46(1):2-18. doi: 10.4143/crt.2014.46.1.2. Epub 2014 Jan 15. Review.</citation>
    <PMID>24520218</PMID>
  </reference>
  <reference>
    <citation>Prokopieva VD, Yarygina EG, Bokhan NA, Ivanova SA. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies. Oxid Med Cell Longev. 2016;2016:2939087. doi: 10.1155/2016/2939087. Epub 2016 Jan 24. Review.</citation>
    <PMID>26904160</PMID>
  </reference>
  <reference>
    <citation>Dandawate PR, Subramaniam D, Padhye SB, Anant S. Bitter melon: a panacea for inflammation and cancer. Chin J Nat Med. 2016 Feb;14(2):81-100. doi: 10.1016/S1875-5364(16)60002-X. Review.</citation>
    <PMID>26968675</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

